Home » Stocks » TPTX

Turning Point Therapeutics, Inc. (TPTX)

Stock Price: $65.06 USD -2.51 (-3.71%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 3.20B
Revenue (ttm) 50.21M
Net Income (ttm) -132.08M
Shares Out 49.15M
EPS (ttm) -3.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $65.06
Previous Close $67.57
Change ($) -2.51
Change (%) -3.71%
Day's Open 67.59
Day's Range 64.98 - 67.78
Day's Volume 371,964
52-Week Range 54.43 - 141.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

3 weeks ago - GlobeNewsWire

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

1 month ago - GlobeNewsWire

SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

1 month ago - GlobeNewsWire

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, toda...

1 month ago - GlobeNewsWire

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, toda...

2 months ago - GlobeNewsWire

Presentations Planned at Annual Meeting of American Association for Cancer Research, Held Virtually April 9-14 Presentations Planned at Annual Meeting of American Association for Cancer Research, Held V...

3 months ago - GlobeNewsWire

Turning Point Therapeutics Inc (NASDAQ: TPTX) has reported initial data from the ongoing Phase 1/2 SWORD-1 study evaluating its RET inhibitor drug candidate, TPX-0046, in adult subjects with advanced or...

3 months ago - Benzinga

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, to...

3 months ago - GlobeNewsWire

Barbara Bodem Joins Board, Appointed Chair of Audit Committee

3 months ago - GlobeNewsWire

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, an...

4 months ago - GlobeNewsWire

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, to...

4 months ago - GlobeNewsWire

This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?

5 months ago - The Motley Fool

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, wil...

5 months ago - GlobeNewsWire

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

Other stocks mentioned: ONCT, ORGO, RDUS, USNA
5 months ago - Zacks Investment Research

If you screen the market for stocks that have a current ratio higher than 2 and more working capital than long-term debt, as Benjamin Graham, the pioneer of value investing, recommended, the chances tha...

Other stocks mentioned: ASND, GH
5 months ago - GuruFocus

Company to Participate in Two Q&A Sessions, Including a Joint Discussion with Zai Lab Company to Participate in Two Q&A Sessions, Including a Joint Discussion with Zai Lab

5 months ago - GlobeNewsWire

SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, ann...

5 months ago - GlobeNewsWire

SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

6 months ago - GlobeNewsWire

Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point's MET/SRC/CSF1R Inhibitor, in Greater China

6 months ago - GlobeNewsWire

TPTX has demonstrated solid competitive data for its lead asset. The company, after two rounds of dilution, is heavy with cash.

6 months ago - Seeking Alpha

Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Planned for Presentation at Upcoming World Conference on Lung Cancer Updated Data from TRIDENT-1 Stu...

7 months ago - GlobeNewsWire

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

Other stocks mentioned: INSM, AUPH, CYTK, NEO
7 months ago - Insider Monkey

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

8 months ago - GlobeNewsWire

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

8 months ago - GlobeNewsWire

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

8 months ago - GlobeNewsWire

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

8 months ago - GlobeNewsWire

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

8 months ago - GlobeNewsWire

SAN DIEGO, Oct. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

9 months ago - GlobeNewsWire

Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022 Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022

9 months ago - GlobeNewsWire

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, tod...

9 months ago - GlobeNewsWire

Two Additional Abstracts Selected for Poster Presentations of Preclinical Data for Lead Drug Candidate Repotrectinib Two Additional Abstracts Selected for Poster Presentations of Preclinical Data for Le...

9 months ago - GlobeNewsWire

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, to...

9 months ago - GlobeNewsWire

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, ...

10 months ago - GlobeNewsWire

SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, ...

10 months ago - GlobeNewsWire

Preeminent Leaders in Cancer Signaling Pathways and Dysregulated Protein Kinases to Advise Company’s Early Pipeline Development Preeminent Leaders in Cancer Signaling Pathways and Dysregulated Protein K...

10 months ago - GlobeNewsWire

SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, t...

11 months ago - GlobeNewsWire

Turning Point Therapeutics (TPTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, t...

11 months ago - GlobeNewsWire

Turning Point Therapeutics (TPTX) delivered earnings and revenue surprises of 14.58% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, t...

11 months ago - GlobeNewsWire

SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, t...

11 months ago - GlobeNewsWire

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, t...

1 year ago - GlobeNewsWire

Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.

1 year ago - The Motley Fool

Next Generation ALK Inhibitor Candidate, TPX-0131, Overcomes ALK Resistant Mutations in Preclinical Models Next Generation ALK Inhibitor Candidate, TPX-0131, Overcomes ALK Resistant Mutations in Preclin...

1 year ago - GlobeNewsWire

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, to...

1 year ago - GlobeNewsWire

SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, to...

1 year ago - GlobeNewsWire

Turning Point Therapeutics (NASDAQ: TPTX) shares are trading higher on Wednesday.

1 year ago - Benzinga

Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, to...

1 year ago - GlobeNewsWire

About TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NT... [Read more...]

Industry
Biotechnology
IPO Date
Apr 17, 2019
Stock Exchange
NASDAQ
Ticker Symbol
TPTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for TPTX stock is "Strong Buy." The 12-month stock price forecast is 152.50, which is an increase of 134.40% from the latest price.

Price Target
$152.50
(134.40% upside)
Analyst Consensus: Strong Buy